Amarin's Off-Label Victory Opens Door To More Injury Claims

By Sindhu Sundar (August 10, 2015, 9:26 PM EDT) -- Amarin Pharma Inc.'s landmark win in its New York federal suit against the U.S. Food and Drug Administration upholds drugmakers' right to truthfully promote their products' unapproved uses, but attorneys say this expanded marketing can inadvertently supply more fodder — without the FDA's imprimatur — for failure-to-warn lawsuits....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!